Abraxane — Total Revenues
Bristol-Myers Squibb Abraxane — Total Revenues decreased by 29.5% to $74.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 70.8%, from $253.00M to $74.00M. Over 3 years (FY 2021 to FY 2024), Abraxane — Total Revenues shows a downward trend with a -9.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market demand and successful clinical adoption, while a decrease often signals increased generic competition, loss of exclusivity, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Abraxane, a chemotherapy medic...
Peer comparison
Comparable to specific product-line revenue metrics reported by other large-cap pharmaceutical companies, particularly those with mature oncology portfolios facing generic or biosimilar entry.
bmy_segment_abraxane_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $296.00M | $266.00M | $305.00M | $214.00M | $241.00M | $177.00M | $179.00M | $239.00M | $258.00M | $260.00M | $247.00M | $217.00M | $231.00M | $253.00M | $174.00M | $105.00M | $105.00M | $74.00M |
| QoQ Change | — | -10.1% | +14.7% | -29.8% | +12.6% | -26.6% | +1.1% | +33.5% | +7.9% | +0.8% | -5.0% | -12.1% | +6.5% | +9.5% | -31.2% | -39.7% | +0.0% | -29.5% |
| YoY Change | — | — | — | — | -18.6% | -33.5% | -41.3% | +11.7% | +7.1% | +46.9% | +38.0% | -9.2% | -10.5% | -2.7% | -29.6% | -51.6% | -54.5% | -70.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's abraxane — total revenues?
- Bristol-Myers Squibb (BMY) reported abraxane — total revenues of $74.00M in Q3 2025.
- How has Bristol-Myers Squibb's abraxane — total revenues changed year-over-year?
- Bristol-Myers Squibb's abraxane — total revenues decreased by 70.8% year-over-year, from $253.00M to $74.00M.
- What is the long-term trend for Bristol-Myers Squibb's abraxane — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's abraxane — total revenues has grown at a -9.5% compound annual growth rate (CAGR), from $1.18B to $875.00M.
- What does abraxane — total revenues mean?
- Total global revenue generated from the sales of the oncology drug Abraxane.